In the unrelenting pulse of our arteries, where blood surges with every heartbeat, the lining of vessels endures a constant mechanical lashing. This frictional force, known as shear stress, is not uniform. In straight sections of vessels, high, laminar shear maintains a smooth, quiescent endothelium. But where arteries branch or curve, disturbed, low shear stress creates a cellular landscape primed for disease. It is here, in these turbulent microenvironments, that atherosclerotic plaques begin their silent growth, soaking up lipids and fanning chronic inflammation. For decades, the molecular mechanisms translating this mechanical itch into biochemical scars have been a subject of intense investigation. Now, a new study published in Nature Communications rewires that circuitry by pinpointing an unexpected culprit: the endothelial cannabinoid CB1 receptor, a protein famously known to mediate the psychoactive effects of cannabis, but which, on the cells lining our vessels, acts as a mechanosensor that drives arterial damage when flow turns angry.
The CB1 receptor is widely recognized for its role in the brain, where it modulates appetite, mood, and pain. It is also the target of the endocannabinoid system, a lipid signaling network that includes the body’s own cannabis-like molecules, anandamide and 2-arachidonoylglycerol. Outside the central nervous system, CB1 receptors are present on endothelial cells, yet their physiological role in vascular biology has remained curiously opaque. Previous pharmacological attempts to block CB1 for metabolic benefit led to the infamous failure of rimonabant, a systemic antagonist that triggered severe psychiatric side effects because it crossed into the brain. The new work, led by Chen, Prabhu, Li and colleagues, elegantly sidesteps that pitfall by focusing solely on endothelial CB1. Using a sophisticated genetic mouse model in which the CB1 receptor is deleted exclusively from endothelial cells, the team asked a precise question: does this receptor interpret disturbed blood flow to ignite the inflammatory cascade that precedes atherosclerosis?
To answer this, the researchers surgically imposed disturbed shear stress on the carotid arteries of mice. In normal animals, this procedure reliably triggers a characteristic response: endothelial cells activate, express adhesion molecules like VCAM-1 that snag circulating monocytes, and begin greedily internalizing modified low-density lipoprotein (LDL), becoming lipid-laden foam cells. However, in endothelial-specific CB1 knockout mice, that pathological script was torn up. Arterial inflammation was dramatically reduced, with levels of key pro-inflammatory cytokines plummeting. Moreover, lipid uptake was significantly blunted, and the expression of scavenger receptors such as LOX-1 and CD36—molecular gateways for oxidized LDL—was suppressed. The endothelium became markedly resistant to the atherogenic assault, not through a change in systemic lipid levels, but because the local mechanosensory alarm had been silenced.
The mechanistic thread tying shear stress to CB1 activation proved to be a cascade of lipid signaling and kinase phosphorylation. Disturbed flow elevated the production of endocannabinoid ligands within endothelial cells themselves, creating an autocrine loop. The binding of these lipids to CB1 triggered the internalization of the receptor and a rapid downstream activation of the mitogen-activated protein kinase (MAPK) p38, a stress-responsive kinase long implicated in inflammatory gene expression. This signal then converged on the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), the master conductor of vascular inflammation. In the knockout mice, this flow-induced p38-NF-κB axis was crippled, preventing the endothelium from flipping its inflammatory switch even under sustained turbulent flow. This places endothelial CB1 directly at the nexus of a mechanotransduction pathway that converts physical force into a pro-atherogenic transcriptional program.
What makes this finding particularly provocative is the receptor’s role in lipid handling. It was not simply that the endothelial cells attracted fewer immune cells; they also actively refused to accumulate lipid droplets. The deficient endothelium showed reduced expression of lipoprotein lipase, an enzyme that docks on the vascular surface and liberates fatty acids from circulating triglycerides, making them available for cellular uptake. Furthermore, the internalization of modified LDL was curtailed, effectively starving the developing plaque of its core constituent. This dual blockade of inflammation and lipid loading suggests that endothelial CB1 orchestrates a coordinated, self-reinforcing pathogenic program that seeds the earliest visible atherosclerotic lesions, the fatty streaks.
The implications extend far beyond transgenic mice. Disturbed shear stress is not merely a laboratory curiosity; it is the universal initiator of atherosclerosis in geometries like the carotid sinus, coronary bifurcations, and the aortic arch in humans. Identifying a receptor that acts as a selective amplifier of injury at these sites raises the tantalizing prospect of a drug that could armor high-risk vascular regions without touching the systemic lipid profile or the brain’s delicate cannabinoid system. Because the knockout animals showed no obvious developmental vascular defects or changes in blood pressure, the therapeutic window appears promising. The side-effect profile that doomed global CB1 antagonists would, in theory, be entirely avoided by developing endothelial-restricted nanocarriers or small molecules that cannot penetrate the blood-brain barrier.
The study also recontextualizes the endocannabinoid system as a critical, intrinsic regulator of vascular mechanobiology, independent of its better-known central roles. It hints that the same cannabinoid receptor that gives cannabis its appetite-stimulating and euphoric properties has been evolutionarily co-opted by the endothelium as an inflammatory rheostat. This is a stark reminder that receptors often moonlight in tissues far removed from their canonical homes, fulfilling entirely unexpected physiological or pathological duties. The presence of a complete, locally operating endocannabinoid loop on the endothelium—complete with enzymatic machinery for synthesizing and degrading ligands—positions it as a rapid-response module to physical insult.
While the work is a preclinical tour de force, it also opens the door to novel diagnostic strategies. Imaging probes that detect activated CB1 receptors on the endothelium could identify arterial sites at earliest risk, before plaques calcify and harden. Combined with the emerging understanding of shear-sensitive microRNAs and epigenetic changes, the field is moving toward a picture of atherosclerosis as a disease of disturbed spatial signaling, with CB1 as a high-value target. The challenge now is to translate these genetic deletion studies into pharmacological agents that can be delivered solely to the glycocalyx-studded endothelial surface, a feat of precision medicine that vascular biologists are actively chasing.
Ultimately, Chen and colleagues have unmasked the endothelial cannabinoid CB1 receptor as a master conductor of shear-driven arterial disease. By deleting it specifically from the cells that line vessels, they effectively uncoupled turbulent flow from its toxic inflammatory and lipid-storing consequences. This rewrites a fundamental chapter of atherogenesis and offers a fresh, druggable node for treating the world’s leading killer. The road to the clinic remains long, but the destination—a vessel wall resilient to the very forces that should break it—has never looked more plausible.
Subject of Research: The role of endothelial cannabinoid CB1 receptors in shear stress-induced arterial inflammation and lipid uptake.
Article Title: Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial inflammation and lipid uptake.
Article References:
Chen, B., Prabhu, A., Li, G. et al. Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial inflammation and lipid uptake. Nat Commun 17, 5939 (2026). https://doi.org/10.1038/s41467-026-75214-2
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-75214-2
Keywords: endothelial CB1 receptor, shear stress, atherosclerosis, arterial inflammation, lipid uptake, mechanotransduction, endocannabinoid system, vascular biology, disturbed flow, NF-κB, p38 MAPK, scavenger receptors, lipoprotein lipase, endothelial-specific knockout, targeted therapy.
